Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Bought by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans increased its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 21.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 224,511 shares of the company's stock after acquiring an additional 40,218 shares during the quarter. Thrivent Financial for Lutherans' holdings in Teva Pharmaceutical Industries were worth $4,046,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Claro Advisors LLC purchased a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter worth about $227,000. King Wealth Management Group purchased a new position in Teva Pharmaceutical Industries during the third quarter worth approximately $1,768,000. CIBC Asset Management Inc boosted its holdings in shares of Teva Pharmaceutical Industries by 5.7% in the 3rd quarter. CIBC Asset Management Inc now owns 105,463 shares of the company's stock valued at $1,900,000 after purchasing an additional 5,713 shares during the last quarter. Plato Investment Management Ltd purchased a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter valued at $1,144,000. Finally, D Orazio & Associates Inc. acquired a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth $199,000. 54.05% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Teva Pharmaceutical Industries

In other news, EVP Christine Fox sold 19,388 shares of the company's stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the sale, the executive vice president now owns 44,104 shares in the company, valued at approximately $744,034.48. This represents a 30.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.55% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on TEVA. StockNews.com raised Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research report on Thursday, October 17th. Barclays raised their price target on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an "overweight" rating in a report on Wednesday, October 23rd. JPMorgan Chase & Co. boosted their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a "neutral" rating in a research note on Monday, October 21st. Finally, UBS Group raised their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a "buy" rating in a research note on Tuesday, September 3rd. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $19.67.

Teva Pharmaceutical Industries Stock Down 2.5 %

TEVA stock traded down $0.43 during trading on Monday, reaching $16.69. The stock had a trading volume of 11,620,606 shares, compared to its average volume of 9,232,298. The company has a market capitalization of $18.91 billion, a P/E ratio of -19.87, a PEG ratio of 1.33 and a beta of 0.87. Teva Pharmaceutical Industries Limited has a 1-year low of $9.35 and a 1-year high of $19.31. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. The firm has a fifty day moving average price of $17.67 and a 200 day moving average price of $17.35.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.